Prestige Biologics Co., Ltd. (KOSDAQ:334970)
South Korea · Delayed Price · Currency is KRW 2,760.00
-35.00 (-1.25%)
At close: Feb 27, 2026
Prestige Biologics Income Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 19,240 | 12,533 | 2,169 | 1,746 | 15.57 | 3,227 |
Other Revenue | - | - | - | -0 | -0 | - |
| 19,240 | 12,533 | 2,169 | 1,746 | 15.57 | 3,227 | |
Revenue Growth (YoY) | 397.28% | 477.82% | 24.24% | 11115.88% | -99.52% | - |
Cost of Revenue | 29,428 | 28,517 | 11,013 | 1,252 | 24.28 | 880.08 |
Gross Profit | -10,188 | -15,984 | -8,844 | 493.75 | -8.71 | 2,347 |
Selling, General & Admin | 6,923 | 8,992 | 9,695 | 7,639 | 5,202 | 3,770 |
Research & Development | 12,497 | 2,588 | 9,301 | 31,848 | 30,970 | 25,097 |
Amortization of Goodwill & Intangibles | 50.3 | 49.06 | 51.91 | 47.89 | 49.36 | 50.98 |
Other Operating Expenses | 267.4 | 340.46 | 417.59 | 237.71 | 180.45 | 82.61 |
Operating Expenses | 24,611 | 17,698 | 24,586 | 40,536 | 36,623 | 29,184 |
Operating Income | -34,799 | -33,682 | -33,430 | -40,043 | -36,631 | -26,837 |
Interest Expense | -7,068 | -8,734 | -11,769 | -5,273 | -3,929 | -763.51 |
Interest & Investment Income | 164.17 | 519.37 | 1,468 | 853.79 | 700.85 | 265.21 |
Currency Exchange Gain (Loss) | -446.01 | 3,243 | -4,690 | -4,624 | -9,537 | 296.68 |
Other Non Operating Income (Expenses) | 13,916 | 11,191 | 18,957 | 10,222 | 257.62 | -12,339 |
EBT Excluding Unusual Items | -28,233 | -27,463 | -29,465 | -38,863 | -49,138 | -39,378 |
Gain (Loss) on Sale of Assets | -1.74 | -6.86 | 90.87 | 67.29 | 66.42 | - |
Asset Writedown | - | - | - | -646.03 | -646.03 | - |
Pretax Income | -28,235 | -27,469 | -29,374 | -39,442 | -49,718 | -39,378 |
Net Income | -28,235 | -27,469 | -29,374 | -39,442 | -49,718 | -39,378 |
Net Income to Common | -28,235 | -27,469 | -29,374 | -39,442 | -49,718 | -39,378 |
Shares Outstanding (Basic) | 82 | 74 | 61 | 59 | 52 | 44 |
Shares Outstanding (Diluted) | 82 | 74 | 61 | 59 | 52 | 44 |
Shares Change (YoY) | 34.23% | 20.50% | 4.32% | 13.35% | 16.43% | 25.46% |
EPS (Basic) | -344.02 | -372.51 | -480.00 | -672.37 | -960.73 | -885.98 |
EPS (Diluted) | -344.02 | -372.51 | -480.00 | -672.37 | -960.73 | -885.98 |
Free Cash Flow | -4,780 | -23,534 | -16,867 | -60,265 | -118,767 | -123,142 |
Free Cash Flow Per Share | -58.24 | -319.14 | -275.63 | -1027.35 | -2295.00 | -2770.62 |
Gross Margin | -52.95% | -127.53% | - | 28.28% | -55.97% | 72.73% |
Operating Margin | -180.87% | -268.74% | -1541.23% | -2293.61% | -235333.31% | -831.68% |
Profit Margin | -146.75% | -219.17% | -1354.23% | -2259.19% | -319407.01% | -1220.33% |
Free Cash Flow Margin | -24.84% | -187.77% | -777.63% | -3451.94% | -763002.69% | -3816.18% |
EBITDA | -20,386 | -20,598 | -22,199 | -31,629 | -28,693 | -22,916 |
EBITDA Margin | -105.95% | -164.35% | - | - | - | - |
D&A For EBITDA | 14,413 | 13,083 | 11,231 | 8,414 | 7,938 | 3,921 |
EBIT | -34,799 | -33,682 | -33,430 | -40,043 | -36,631 | -26,837 |
EBIT Margin | -180.87% | -268.74% | - | - | - | - |
Advertising Expenses | - | 101.46 | 308.97 | - | 53.15 | 39.82 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.